NATCO Pharma financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹735cr−44.7% on Q1 FY26
Net profit
₹207cr−57.0% on Q1 FY26
EBITDA margin
25.4%−17.6 pts on Q1 FY26
EPS
₹11.53−57.0% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue7351,329−44.7%
EBITDA187571−67.3%
EBITDA margin25.4%43.0%−17.6 pts
Profit before tax186572−67.5%
Net profit207480−57.0%
EPS₹11.53₹26.84−57.0%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹735 crNet profit₹207 crNet margin28.1%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
14,195————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
777777441514437
0.00.05.3——
706706273363165
14,124————
3,4854,0784,4303,9992,707
—−7.9%+10.8%+47.7%—
1,0521,4372,1961,751936
30.2%35.2%49.6%43.8%34.6%
8561,2301,9611,565772
1,1451,4191,8831,388715
32.9%34.8%42.5%34.7%26.4%
₹63.93₹79.25₹105.33₹77.56₹39.96
—−24.8%+35.8%+94.1%—
—1,7681,6971,212849
—−391−512−359−206
1,3771,3771,185853644
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NATCOPHARM₹793.00

NATCO Pharma Ltd.

· Pharma & Health
₹ CrorePeersDRREDDYZYDUSLIFESUNPHARMALALPATHLABNEULANDLABNHSAILIFECOHANCEMcap ₹14,195 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————14,194.7
- Cash, Equiv & ST Investments436.9513.9440.8777.1777.1
+ Minority Interest——5.30.00.0
+ Total Debt165.0363.2273.1706.4706.4
Enterprise Value————14,124.0
Revenue2,707.13,998.84,429.54,078.33,484.6
Growth %, YoY—+47.7+10.8-7.9—
EBITDA935.61,751.42,196.01,436.51,052.0
Margin %34.5643.8049.5835.2230.19
EBIT771.81,564.61,960.81,229.9855.9
Net Income715.31,388.31,883.41,418.51,144.7
Margin %26.4234.7242.5234.7832.85
EPS, Adj (current shares)39.9677.56105.3379.2563.93
Growth %, YoY—+94.1+35.8-24.8—
Cash from Operations849.11,211.61,696.81,768.3—
Capital Expenditures-205.6-358.7-511.6-391.1—
Free Cash Flow643.5852.91,185.21,377.21,377.2
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

NATCO Pharma financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

NATCO Pharma (NSE: NATCOPHARM) had a market capitalisation of ₹14,097 crore at the 29 October 2026 close (₹787.55 a share), a PE ratio of 12.3 on the last four quarters' profit and a price-to-book ratio of 1.53. In FY26 its consolidated net profit was ₹1,419 crore on revenue of ₹4,078 crore; in Q1 FY27 (April–June 2026) it was ₹207 crore, down 57.0% year on year. Its debt-to-equity ratio was 0.08 on 31 March 2026. Promoters held 49.39% of the shares on 30 September 2026.

Share price used
₹787.55 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

NATCO Pharma at a glance · consolidated

Market cap
₹14,097 Crat ₹787.55 · 29 Oct close
PE ratio (last 4 quarters)
12.39.9 on FY26 profit
Price to book (PB)
1.53book value ₹515.15 a share
ROE (FY26)
16.9%−11.2 pts vs FY25ROCE 14.4%
Debt to equity
0.08net cash ₹1,423 Cr
Promoter holding
49.39%unchanged vs 30 Jun 202630 September 2026
Dividend yield
0.57%₹4.50 a share in 12 months
Net worth
₹9,221 Cr+21.2% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹1,377 Cr+16.2% vs FY25

Questions

What is the NATCO Pharma PE ratio today?

NATCO Pharma's PE ratio is 12.3 at the 29 October 2026 close (₹787.55 a share): a market capitalisation of ₹14,097 crore divided by consolidated net profit of ₹1,144 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹1,419 crore) it is 9.9.

What is the NATCO Pharma net worth?

NATCO Pharma's net worth — shareholders' equity in its consolidated balance sheet — was ₹9,221 crore on 31 March 2026, up 21.2% from ₹7,607 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹14,097 crore at the 29 October 2026 close.

What is the NATCO Pharma book value per share?

NATCO Pharma's book value per share was ₹515.15 on 31 March 2026: shareholders' equity of ₹9,221 crore divided by the 17.9 crore shares in issue, up 21.2% from ₹424.97 a year earlier. The share price at the 29 October 2026 close was ₹787.55.

What is the NATCO Pharma PB ratio (price to book value)?

NATCO Pharma's price-to-book (PB) ratio is 1.53 at the 29 October 2026 close: a market capitalisation of ₹14,097 crore divided by shareholders' equity (book value) of ₹9,221 crore on 31 March 2026. That is a book value of ₹515.15 per share against a share price of ₹787.55.

What is the NATCO Pharma ROE and ROCE?

In FY26, NATCO Pharma's return on equity (ROE) was 16.9% and its return on capital employed (ROCE) was 14.4%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 28.0% and ROCE 28.8%.

What is the NATCO Pharma dividend yield?

NATCO Pharma's dividend yield is 0.57% at the 29 October 2026 close: dividends of ₹4.50 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹787.55. They were ₹1.50 on 20 August 2026 (interim), ₹1.50 on 18 February 2026 (interim) and ₹1.50 on 20 November 2025 (interim).

What is the NATCO Pharma market cap?

NATCO Pharma's market capitalisation was ₹14,097 crore at the 29 October 2026 close: 17.9 crore shares at ₹787.55 each.

Is NATCO Pharma debt free?

No. NATCO Pharma had borrowings of ₹706 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.08. Its cash and current investments were ₹2,129 crore, so it held net cash of ₹1,423 crore.

What is the NATCO Pharma EPS?

NATCO Pharma's basic earnings per share (EPS) were ₹79.20 in FY26, against ₹105.26 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹63.89.

What is the NATCO Pharma debt to equity ratio?

NATCO Pharma's debt-to-equity ratio was 0.08 on 31 March 2026: borrowings of ₹706 crore against total equity of ₹9,221 crore. A year earlier, on 31 March 2025, it was 0.04.

What is the NATCO Pharma dividend in 2026 and its record date?

In 2026, NATCO Pharma has declared two dividends totalling ₹3 a share: ₹1.50 (interim) with record date 18 February 2026 and ₹1.50 (interim) with record date 20 August 2026.

What is the NATCO Pharma promoter holding?

Promoters held 49.39% of NATCO Pharma on 30 September 2026, down 0.03 percentage points from 49.42% the previous quarter and down 0.09 percentage points from 49.48% a year earlier, according to the shareholding pattern filed with NSE.

What is the NATCO Pharma shareholding pattern?

On 30 September 2026, NATCO Pharma's shares were held by promoters 49.39%, foreign portfolio investors (FII/FPI) 16.00%, domestic institutions (DII) 6.16% (including mutual funds at 2.25%) and retail and other non-institutional investors 28.45%. Over the year, FII holding was up 1.91 percentage points from 14.09% and DII holding was up 0.29 percentage points from 5.87%.

What are the NATCO Pharma latest quarterly results?

NATCO Pharma's latest results are for Q1 FY27 (April–June 2026), filed on 14 August 2026: consolidated net profit ₹207 crore, down 57.0% from ₹481 crore in Q1 FY26; revenue from operations ₹735 crore, down 44.7% year on year.

How does the NATCO Pharma PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit, NATCO Pharma's PE ratio is 9.9, the lowest of the four: Dr Reddy's 26.8, Zydus Lifesciences 23.5 and Sun Pharma 36.8, a peer average of 29.0. Each is the company's market capitalisation at that price divided by its FY26 net profit.

What is the NATCO Pharma free cash flow?

In FY26, NATCO Pharma generated ₹1,768 crore of cash from operations and spent ₹391 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹1,377 crore. In FY25 it was ₹1,185 crore.

What is the NATCO Pharma revenue and profit in FY26?

In FY26 (April 2025–March 2026), NATCO Pharma's consolidated net profit was ₹1,419 crore, down 24.8% from ₹1,885 crore in FY25, on revenue from operations of ₹4,078 crore (down 7.9%). Over three years, from FY23, net profit was up 98.3%.

When are the NATCO Pharma next results?

NATCO Pharma will announce its Q2 FY27 results (July–September 2026) on Friday, 13 November 2026, the date of the board meeting it has notified to the exchanges.

How does NATCO Pharma compare with its peers?

On FY26 consolidated figures, against Dr Reddy's, Zydus Lifesciences and Sun Pharma: NATCO Pharma's operating margin of 30.2% is the highest of the four (Dr Reddy's 13.0%, Zydus Lifesciences 26.0%, Sun Pharma 25.3%; peer average 21.5%); its return on equity of 16.9% is the second highest of the four (Dr Reddy's 11.8%, Zydus Lifesciences 19.7%, Sun Pharma 14.7%; peer average 15.4%); its revenue growth over three years of 14.6% a year is the second highest of the four (Dr Reddy's 11.0% a year, Zydus Lifesciences 16.4% a year, Sun Pharma 10.0% a year; peer average 12.4% a year).

NATCO Pharma vs Dr Reddy's: how do they compare?

In FY26, NATCO Pharma earned net profit of ₹1,419 crore on revenue of ₹4,078 crore, against ₹4,196 crore on ₹33,700 crore for Dr Reddy's. NATCO Pharma's operating margin was 30.2% (Dr Reddy's 13.0%) and its return on equity 16.9% (Dr Reddy's 11.8%). At the 29 October 2026 close, NATCO Pharma's market capitalisation was ₹14,097 crore against ₹1,12,308 crore for Dr Reddy's, and its PE ratio on FY26 profit 9.9 against 26.8.

Where do these NATCO Pharma figures come from?

From NATCO Pharma's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.